What's Happening? Rosen Law Firm, a prominent global investor rights law firm, has issued a reminder to investors who purchased securities of Altimmune, Inc. between August 10, 2023, and June 25, 2025. The firm highlights the importance of the upcoming October 6, 2025, deadline for lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Altimmune misled investors regarding the results of its IMPACT Phase 2b MASH trial, failing to meet a critical statistical significance marker for the fibrosis reduction primary endpoint. Investors who suffered losses due to these alleged misrepresentations may be entitled to compensation through a contingency fee arrangement, which requires no out-of-pocket costs. Why It's Important? The class action lawsuit against Altimmune is significant as it underscores the importance of transparency and accuracy in corporate communications, particularly in the pharmaceutical sector. Misleading information can lead to substantial financial losses for investors, affecting their trust and willingness to invest in similar ventures. The outcome of this lawsuit could set a precedent for how companies report trial results and manage investor expectations. It also highlights the role of law firms like Rosen in protecting investor rights and ensuring accountability in the securities market. What's Next? Investors interested in joining the class action must submit their applications by October 6, 2025, to be considered for the lead plaintiff role. The court will then decide on the certification of the class, which will determine the representation of affected investors. As the case progresses, Altimmune may face increased scrutiny from regulators and investors, potentially impacting its market reputation and stock performance. The resolution of this lawsuit could influence future corporate governance practices and investor relations strategies within the industry. AI Generated Content

For the benefit of users - Parts of this article may include content generated using AI tools. Our teams are making active and commercially reasonable efforts to moderate all AI generated content. Our moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. We encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. We maintain that all AI generated content on our platform is for entertainment purposes only. To know more about how we use AI, you can write to us at

Close AI Generated Content